| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rothmund-Thomson Syndrome | 20 | 2023 | 48 | 5.670 |
Why?
|
| Osteosarcoma | 20 | 2022 | 258 | 4.330 |
Why?
|
| RecQ Helicases | 16 | 2022 | 62 | 4.120 |
Why?
|
| Bone Neoplasms | 15 | 2022 | 428 | 3.500 |
Why?
|
| Mutation | 15 | 2023 | 5734 | 0.840 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 152 | 0.680 |
Why?
|
| Adenosine Triphosphatases | 4 | 2005 | 206 | 0.650 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 293 | 0.630 |
Why?
|
| DNA Helicases | 4 | 2005 | 223 | 0.630 |
Why?
|
| Carcinogenesis | 2 | 2022 | 332 | 0.530 |
Why?
|
| Neutropenia | 2 | 2010 | 202 | 0.510 |
Why?
|
| Fractures, Bone | 1 | 2017 | 180 | 0.500 |
Why?
|
| Bone Development | 1 | 2015 | 56 | 0.490 |
Why?
|
| Induced Pluripotent Stem Cells | 4 | 2022 | 192 | 0.470 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 106 | 0.450 |
Why?
|
| Indians, North American | 2 | 2010 | 58 | 0.420 |
Why?
|
| Limb Deformities, Congenital | 2 | 2015 | 105 | 0.410 |
Why?
|
| Osteogenesis | 3 | 2024 | 154 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 1889 | 0.380 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 712 | 0.360 |
Why?
|
| Metatarsal Bones | 1 | 2010 | 8 | 0.350 |
Why?
|
| Open Reading Frames | 1 | 2010 | 211 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2010 | 150 | 0.350 |
Why?
|
| Fibroblasts | 3 | 2023 | 878 | 0.340 |
Why?
|
| Aging | 1 | 2016 | 1165 | 0.330 |
Why?
|
| Serine Endopeptidases | 2 | 2024 | 175 | 0.320 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 1677 | 0.310 |
Why?
|
| Mutagens | 1 | 2008 | 84 | 0.300 |
Why?
|
| Humans | 41 | 2024 | 122296 | 0.290 |
Why?
|
| Drug Resistance | 1 | 2008 | 257 | 0.290 |
Why?
|
| Osteoblasts | 3 | 2024 | 151 | 0.280 |
Why?
|
| Neoplasms | 3 | 2017 | 2753 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1250 | 0.240 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2024 | 9 | 0.240 |
Why?
|
| Child | 16 | 2021 | 24064 | 0.240 |
Why?
|
| Adolescent | 15 | 2019 | 18940 | 0.240 |
Why?
|
| Child, Preschool | 11 | 2019 | 13777 | 0.220 |
Why?
|
| Receptor, ErbB-2 | 3 | 2016 | 497 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2014 | 3050 | 0.210 |
Why?
|
| E2F3 Transcription Factor | 1 | 2022 | 11 | 0.200 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2022 | 9 | 0.200 |
Why?
|
| Heterozygote | 2 | 2022 | 675 | 0.200 |
Why?
|
| Electron Transport Complex I | 1 | 2021 | 32 | 0.200 |
Why?
|
| Spliceosomes | 1 | 2022 | 48 | 0.200 |
Why?
|
| T-Lymphocytes | 3 | 2015 | 1678 | 0.190 |
Why?
|
| Radius | 2 | 2015 | 25 | 0.190 |
Why?
|
| Animals | 12 | 2024 | 33721 | 0.190 |
Why?
|
| DNA Replication | 2 | 2016 | 345 | 0.180 |
Why?
|
| Mice | 9 | 2024 | 17546 | 0.180 |
Why?
|
| Adult | 12 | 2018 | 28733 | 0.170 |
Why?
|
| Apc1 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2019 | 3 | 0.170 |
Why?
|
| Anaphase-Promoting Complex-Cyclosome | 1 | 2019 | 20 | 0.170 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 346 | 0.170 |
Why?
|
| Male | 17 | 2019 | 59522 | 0.170 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 210 | 0.160 |
Why?
|
| Bone and Bones | 2 | 2014 | 261 | 0.160 |
Why?
|
| Craniosynostoses | 2 | 2015 | 131 | 0.160 |
Why?
|
| Survivors | 1 | 2021 | 345 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 178 | 0.150 |
Why?
|
| Genomic Instability | 1 | 2020 | 229 | 0.150 |
Why?
|
| Methotrexate | 1 | 2019 | 341 | 0.150 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2017 | 4 | 0.150 |
Why?
|
| Female | 16 | 2019 | 64883 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2017 | 42 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2016 | 1520 | 0.140 |
Why?
|
| Bone Remodeling | 1 | 2017 | 54 | 0.140 |
Why?
|
| DNA Repair | 2 | 2017 | 583 | 0.140 |
Why?
|
| Receptors, Notch | 2 | 2009 | 206 | 0.140 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 54 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 1296 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2016 | 96 | 0.130 |
Why?
|
| Infant | 7 | 2010 | 12302 | 0.130 |
Why?
|
| Patella | 1 | 2015 | 28 | 0.120 |
Why?
|
| Hydroxyurea | 2 | 2023 | 81 | 0.120 |
Why?
|
| Midwestern United States | 1 | 2015 | 17 | 0.120 |
Why?
|
| Bone Density | 1 | 2017 | 307 | 0.120 |
Why?
|
| Anal Canal | 1 | 2015 | 80 | 0.120 |
Why?
|
| Dwarfism | 1 | 2015 | 98 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2015 | 479 | 0.120 |
Why?
|
| Skull Neoplasms | 1 | 2014 | 15 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 333 | 0.110 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2015 | 122 | 0.110 |
Why?
|
| Models, Biological | 2 | 2017 | 1438 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2014 | 4511 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 650 | 0.110 |
Why?
|
| Gelatinases | 1 | 2013 | 14 | 0.110 |
Why?
|
| Receptors, Antigen | 1 | 2013 | 33 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2015 | 658 | 0.110 |
Why?
|
| Young Adult | 6 | 2018 | 8760 | 0.100 |
Why?
|
| Sarcoma | 1 | 2015 | 197 | 0.100 |
Why?
|
| DNA Damage | 2 | 2023 | 516 | 0.100 |
Why?
|
| Base Sequence | 2 | 2010 | 3109 | 0.100 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 3865 | 0.100 |
Why?
|
| Mice, Transgenic | 2 | 2015 | 2441 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 1674 | 0.090 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 296 | 0.090 |
Why?
|
| Cellular Senescence | 2 | 2023 | 159 | 0.090 |
Why?
|
| Phenotype | 4 | 2016 | 4151 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2010 | 792 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 215 | 0.090 |
Why?
|
| Prognosis | 3 | 2016 | 4488 | 0.090 |
Why?
|
| Genotype | 2 | 2008 | 2525 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 295 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 1615 | 0.080 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2008 | 8 | 0.080 |
Why?
|
| Mutagenicity Tests | 1 | 2008 | 36 | 0.080 |
Why?
|
| Radiation, Ionizing | 1 | 2008 | 42 | 0.080 |
Why?
|
| Registries | 1 | 2015 | 1367 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 790 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 152 | 0.070 |
Why?
|
| Camptothecin | 1 | 2008 | 78 | 0.070 |
Why?
|
| Disease Progression | 1 | 2014 | 1991 | 0.070 |
Why?
|
| Ultraviolet Rays | 1 | 2008 | 204 | 0.070 |
Why?
|
| Risk Factors | 2 | 2019 | 9902 | 0.070 |
Why?
|
| Cisplatin | 1 | 2008 | 255 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2008 | 307 | 0.070 |
Why?
|
| Growth Disorders | 1 | 2008 | 208 | 0.070 |
Why?
|
| Radiography | 1 | 2008 | 804 | 0.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2006 | 47 | 0.060 |
Why?
|
| Cytogenetic Analysis | 2 | 2006 | 79 | 0.060 |
Why?
|
| Age of Onset | 1 | 2007 | 576 | 0.060 |
Why?
|
| Lymphoma | 1 | 2008 | 323 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2007 | 4643 | 0.060 |
Why?
|
| Transfection | 2 | 2008 | 1076 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1871 | 0.060 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2006 | 201 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6291 | 0.060 |
Why?
|
| Homeostasis | 1 | 2008 | 680 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2480 | 0.060 |
Why?
|
| Pluripotent Stem Cells | 1 | 2024 | 76 | 0.060 |
Why?
|
| Blotting, Southern | 1 | 2003 | 217 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2014 | 262 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2003 | 93 | 0.050 |
Why?
|
| Genes, Retinoblastoma | 1 | 2022 | 18 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 3290 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2003 | 459 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2002 | 129 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2021 | 24 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 83 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 93 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2001 | 77 | 0.050 |
Why?
|
| Introns | 1 | 2002 | 303 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2001 | 73 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2001 | 111 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2001 | 92 | 0.050 |
Why?
|
| Retinoblastoma | 1 | 2022 | 108 | 0.050 |
Why?
|
| Karyotyping | 1 | 2001 | 338 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2001 | 100 | 0.050 |
Why?
|
| Trisomy | 1 | 2001 | 104 | 0.050 |
Why?
|
| Retinal Neoplasms | 1 | 2022 | 98 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 288 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2002 | 223 | 0.050 |
Why?
|
| Piperidines | 1 | 2021 | 196 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 523 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2001 | 345 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 2573 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2311 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 962 | 0.040 |
Why?
|
| Cytokines | 2 | 2016 | 1272 | 0.040 |
Why?
|
| Alleles | 1 | 2003 | 1579 | 0.040 |
Why?
|
| Transcriptome | 1 | 2024 | 904 | 0.040 |
Why?
|
| Bloom Syndrome | 1 | 2017 | 5 | 0.040 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2017 | 8 | 0.040 |
Why?
|
| Ataxia Telangiectasia | 1 | 2017 | 16 | 0.040 |
Why?
|
| Aged | 1 | 2015 | 18785 | 0.040 |
Why?
|
| Fanconi Anemia | 1 | 2017 | 49 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 1750 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 1003 | 0.030 |
Why?
|
| DNA | 1 | 2002 | 1606 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1935 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2015 | 12045 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 874 | 0.030 |
Why?
|
| Incidence | 1 | 2003 | 3018 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Middle Aged | 1 | 2015 | 25640 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 157 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2014 | 58 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 95 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2014 | 78 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 744 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 872 | 0.030 |
Why?
|
| Syndrome | 2 | 2008 | 1109 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 113 | 0.030 |
Why?
|
| Skull Base Neoplasms | 1 | 2014 | 35 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 761 | 0.030 |
Why?
|
| Transgenes | 1 | 2014 | 330 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 4282 | 0.030 |
Why?
|
| Gene Order | 1 | 2013 | 78 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 285 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 3448 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2013 | 115 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1468 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 630 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 680 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1008 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 234 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 57 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2011 | 59 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2011 | 59 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 1997 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1413 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 352 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 257 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 285 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 768 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 570 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 261 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1227 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 969 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 741 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 62 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1424 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1084 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1579 | 0.020 |
Why?
|
| Presenilins | 1 | 2008 | 8 | 0.020 |
Why?
|
| Osteosclerosis | 1 | 2008 | 12 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 1000 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2008 | 41 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3528 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2030 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2008 | 114 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 979 | 0.020 |
Why?
|
| Pneumocystis Infections | 1 | 2006 | 3 | 0.020 |
Why?
|
| Agammaglobulinemia | 1 | 2006 | 39 | 0.020 |
Why?
|
| Lung | 1 | 2013 | 1476 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 2782 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 15853 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2008 | 2578 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 7092 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2005 | 8096 | 0.010 |
Why?
|